Zelira Therapeutics Ltd has released a press release.
ZLD Supports Levins Chronic Pain Trial Ethics Approval
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelira Develops Technology and Signs New Licensing Deal
- September 2021 Quarterly Activities Report
- Zelira Raises US$5 Million from US Fund
- Zelira Launches RAF FIVE Acne Treatment Products
- Zelira enters Germany via Exclusive Distribution Agreement
Later from Zelira Therapeutics
- Zelira expands into NZ via exclusive distribution agreement
- Partial Receipt Of Zeliras EDCDM Technology License Fee
- Zelira receives $1.2 million cash R&D Tax Incentive
- December 2021 Quarterly Activities Report
- Appendix 4D & FY22 Interim Financial Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics